• People

    Advanced Search

  • Services
  • All Services

  • Stark & Stark defective drug attorneys are currently representing clients who suffered injuries, including death, heart attack, stroke, blood clots or deep vein thrombosis (DVT) as a result of the use of prescription testosterone medication. These medications include Androgel, AndroDerm, Axiron, Bio-T Gel, Delatestryl, Depo-Testosterone, Fortesta, Testim, Testopel and Striant, which are administered in gel, patch, and injection forms, as well as pellets. If you suffered one or more of these health events while utilizing testosterone therapy, you should immediately contact Stark & Stark for a free, confidential consultation regarding your rights and potential claims.

    The U.S. Food and Drug Administration (FDA) announced on January 31, 2014 that it was investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. The FDA made this decision, and issued this Safety Announcement, as a result of two recent studies which suggested an increased risk of cardiovascular events among groups of men prescribed testosterone therapy.

    The first study was published in November, 2013 in the Journal of the American Medical Association, and was an observational study of older men in the U.S. Veterans Affairs health system. The men in the study had an average age of 60, many had underlying cardiovascular disease, and all were undergoing imaging of the blood vessels of the heart (coronary angiography). (This test assesses a person for coronary artery disease.) All of the men had low serum testosterone, and some of them received testosterone therapy, while others did not. The results of the study suggested a 30 percent increased risk of stroke, heart attack and death in the group that had been prescribed testosterone therapy.

    The second study reported an increased risk of heart attack in older men, as well as in younger men with pre-existing heart disease, who filled a prescription for testosterone therapy. This observational study reported a two-fold increase in the risk of heart attack among men aged 65 years or older in the first 90 days following the first prescription. The same study reported a two- to three-fold increase in the risk of heart attack among men less than 65 years old with a pre-existing history of heart disease, in the first 90 days following a first prescription. The study also found that younger men without a history of heart disease, and who filled a prescription for testosterone therapy, did not have an increased risk of heart attack.

    You should be aware that the FDA has NOT concluded that FDA-approved testosterone treatments increased the risk of these events, and no one should stop taking prescribed testosterone products without first discussing their concerns with their health care professional.

    What is the basis for these potential claims? You’ve seen the plethora of “Low T” commercials on TV. Testosterone is a hormone that is involved with maintaining sex drive, muscle mass, bone health and energy levels. It is common for testosterone levels to decrease for all men as they age, and this is generally viewed as a normal event which does not require medical treatment. It has been suggested that the drug manufacturers are recklessly marketing testosterone treatments in direct-to-consumer advertisements for “Low T” if they are experiencing any number of general symptoms, such as lack of energy, weight gain, decreased sex drive and other natural issues experienced by men as they age. Stephen Colbert, the comedian, has suggested that these “Low T” drugs are being marketed for a “drug industry recognized condition known as ‘growing older’.” It is also suggested that the drug companies conducted this aggressive marketing campaign despite knowing that the risks of this therapy outweigh the benefits for many men. There is also a concern that the drug companies failed to adequately research the risk of stroke or heart attack as a result of using this therapy, especially in men with cardiovascular disease, high cholesterol, blocked arteries, diabetes, obesity and other prior health problems.

    For more than 20 years, product liability lawyers at Stark & Stark have successfully represented victims of defective marketing practices by drug manufacturers. If you or someone you know used one or more of these testosterone therapies and has suffered one or more of these health events, the injured person may be eligible to receive compensation for their damages. Contact Stark & Stark for a free, confidential consultation. Our lawyers work on a contingency fee basis and will review your case at not cost or obligation to you. Please contact us today at 1-800-53-LEGAL (1-800-535-3425) or “LowT@stark-stark.com“.

    Speak with an Experienced Attorney Today

    Firm Highlights

    Stark & Stark Joins Growing Coalition of Law Firms in Defense of Constitutional Principles and the Independence of the Legal Profession

    Stark & Stark has joined hundreds of fellow law firms across the country in filing an amicus brief supporting Perkins Coie, WilmerHale, Jenner...

    Stark & Stark Attorneys Recognized as New Jersey “Super Lawyers” and “Rising Stars” in 2026

    Stark & Stark is pleased to announce that 15 of its attorneys have been selected for inclusion in the list of 2026 New Jersey Super Lawyers,...

    Bruce Stern, Esq. Secures $1,000,000 Settlement in Motor Vehicle Collision Case

    Bruce Stern, Esq. recently secured a $1,000,000 settlement in a motor vehicle collision case.* “This case highlights how quickly things can go...

    Deborah Dunn, Esq. Elected to Board of Directors for Angel Flight East

    Stark & Stark is pleased to announce that Deborah Dunn, Esq., Shareholder and Civil Trial Attorney, has been elected to the Board of Directors...

    Michael Jordan, Esq. Joins the Board of the Lawrence Township Community Foundation

    It is our pleasure to announce that Michael Jordan, Esq. has joined the board of the Lawrence Township Community Foundation, an organization...

    Stark & Stark Opens Newtown, Pennsylvania Location

    Stark & Stark announced the relocation of its Yardley, Pennsylvania office to a new location in Newtown, PA. The new office is now open and...

    Joseph Lemkin, Esq. Named to ROI-NJ Influencers: Power List 2026 – Law

    Stark & Stark is proud to share that Joseph Lemkin, Esq., Shareholder, has been named to the 2026 Influencers: Power List in the Law category...

    Jeffrey A. Krawitz, Esq. and Michael C. Ksiazek, Esq. Secure $1,000,000 Settlement in Medical Malpractice Wrongful Death Case

    Jeffrey A. Krawitz, Esq. and Michael C. Ksiazek, Esq. recently secured a $1,000,000 settlement in a medical malpractice wrongful death...

    Joseph Cullen, Esq. and Nicole Durso, Esq. Secure $2,000,000 Settlement in Personal Injury Matter

    Joseph Cullen, Esq. and Nicole Durso, Esq. recently secured a $2,000,000 settlement in a personal injury matter involving a pedestrian who was struck...

    Stark & Stark Welcomes Susan L. Swatski, Esq. to the Firm

    Continuing in its mission to provide its clients innovative legal solutions to meet their needs, Stark & Stark PC, announced today that Susan L....

    Tim Duggan Wins Eminent Domain Challenge – Case Dismissed

    We are pleased to share that Tim Duggan of our Condemnation, Redevelopment, and Eminent Domain Group was successful in protecting the owner of a...

    James Creegan, Esq. Appointed to Board of The 200 Club of Mercer County

    It is our pleasure to announce that James Creegan, Esq. has been appointed to the Board of Directors of The 200 Club of Mercer County, an...